LIPOCINE INC. news, videos and press releases
For more news please use our advanced search feature.
LIPOCINE INC. - More news...
LIPOCINE INC. - More news...
- Lipocine Announces Positive LPCN 2401 Clinical Results Showing Improved Body Composition in Participants with Obesity
- Lipocine Announces Positive Week 52 Results from LPCN 1148 Phase 2 Study in Patients with Cirrhosis
- Lipocine Announces First Cohort Dosed in Pivotal Study of LPCN 1154
- Lipocine Announces Financial Results for the Full Year Ended December 31, 2023
- Lipocine to Present at 36th Annual Roth Conference
- Lipocine Announces Confirmation of Dosing Regimen for Pivotal Study of LPCN 1154
- Lipocine Announces Continued Commercialization of TLANDO® through Verity Pharmaceuticals
- Lipocine and Verity Pharma Enter into License Agreement for TLANDO® Franchise in the U.S. and Canada
- Lipocine to Present at Biotech Showcase 2024
- Lipocine Releases Late Breaking Presentation on LPCN 1148 Phase 2 Results at The Liver Meeting® 2023
- Lipocine Announces Financial Results for the Third Quarter Ended September 30, 2023
- Lipocine to Present Clinical Data on LPCN 1148 at The Liver Meeting® 2023
- Lipocine Completes Successful Meeting with FDA on LPCN 1154 in Postpartum Depression
- Lipocine to Present at the H.C. Wainwright Annual NASH Investor Conference
- Lipocine to Present at the Cantor Fitzgerald Global Healthcare Conference
- Lipocine Announces Financial Results for the Second Quarter Ended June 30, 2023
- LPCN 1148 Phase 2 Study Meets Primary Endpoint in Patients with Cirrhosis
- Lipocine to Present at H.C. Wainwright Annual Neuropsychiatry Virtual Conference
- Lipocine to Present LPCN 1148 and LPCN 1144 at the EASL Congress 2023
- Positive Topline Clinical Results Support Streamlined Development Pathway for LPCN 1154, Lipocine's Oral Candidate for Rapid Relief of Depression
- Lipocine Announces Financial Results for the First Quarter Ended March 31, 2023
- First Subject Dosed in the Clinical Bridge Study with Lipocine Depression Candidate, LPCN 1154
- Lipocine Announces Pro Rata Distribution of Series B Preferred Stock to its Holders of Common Stock
- Lipocine Announces Financial Results for the Year Ended December 31, 2022
- Lipocine to Present at Biotech Showcase
- Lipocine Completes Enrollment of LPCN 1148 Phase 2 Study for Decompensated Cirrhosis
- Lipocine Announces Financial Results for the Third Quarter Ended September 30, 2022
- Lipocine Announces Senior Leadership Appointments to Advance its CNS-Focused Pipeline
- Lipocine to Present at H.C. Wainwright 6th Annual NASH Investor Conference
- Lipocine to Participate in the Cantor Neurology & Psychiatric Conference